title: Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps.
abstract: BACKGROUND
  Over 30 years ago, we began to develop a nonhuman primate model to study cognitive deficits of age-related neurodegenerative diseases and their neuroanatomical-neurochemical underpinnings for purposes of translating this work toward first pharmacotherapies. This effort produced several notable findings that eventually received consensus support, which we have been asked to review.
  
  
  OBJECTIVE
  A discussion of these findings, in the context of issues and obstacles confronted and principles applied, might facilitate the development of even more effective models and treatments, not only for Alzheimer's disease (AD) but for many other disorders involving cognitive deficits.
  
  
  RESULTS
  Collectively, our research provided first evidence of the following: aged primates can be used as 'models' for human age-related neurodegenerative diseases; key cognitive deficits in early AD share important conceptual similarities to deficits in both aged monkeys as well as non-demented humans (e.g., age-associated memory impairment and mild cognitive impairment); pharmacological intervention can reduce age-related cognitive impairments in animals that are conceptually similar to those seen in human diseases, including AD; cholinergics would likely be the first approved therapeutics for AD; and that many other classes of drugs would not likely succeed.
  
  
  CONCLUSIONS
  Despite the early promise shown by behavioral/functional approaches to develop treatment strategies, the dramatic shift in focus away from behavioral outcomes in animal neurodegenerative research that began 20 years ago has compromised further progress and continues to impede our ability to understand how these diseases impair human cognition and what pathways might lead to effective therapies. Principles applied successfully in the past should provide guidance for facilitating efforts in the future.
authors.affiliation: Ceregene, Inc., 9381 Judicial Dr., Suite 130, San Diego, CA 92121, USA. rtbartus@ceregene.com
authors.forename: Raymond T
authors.initials: RT
authors.lastname: Bartus
authors.forename: Reginald L
authors.initials: RL
authors.lastname: Dean
mesh_terms: D000375:Aging / Q000502:physiology; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology*; D000818:Animals; D003072:Cognition Disorders / Q000188:drug therapy* / Q000523:psychology*; D004195:Disease Models, Animal; D000882:Haplorhini; D006801:Humans; D008569:Memory Disorders / Q000188:drug therapy / Q000523:psychology; D051379:Mice; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000523:psychology; D011597:Psychomotor Performance / Q000187:drug effects; D051381:Rats